INDIVIOR PLC (INDV) Stock Fundamental Analysis
NASDAQ:INDV - Nasdaq - GB00BN4HT335 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to INDV. INDV was compared to 194 industry peers in the Pharmaceuticals industry. INDV has an average financial health and profitability rating. INDV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year INDV has reported negative net income.
INDV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
In multiple years INDV reported negative operating cash flow during the last 5 years.
1.2 Ratios
INDV has a Return On Assets of -4.00%. This is in the better half of the industry: INDV outperforms 77.32% of its industry peers.
INDV has a Return On Invested Capital of 111.88%. This is amongst the best in the industry. INDV outperforms 100.00% of its industry peers.
INDV had an Average Return On Invested Capital over the past 3 years of 43.06%. This is significantly above the industry average of 14.87%.
The 3 year average ROIC (43.06%) for INDV is below the current ROIC(111.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4% | ||
| ROE | N/A | ||
| ROIC | 111.88% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
1.3 Margins
In the last couple of years the Profit Margin of INDV has declined.
INDV has a Operating Margin of 25.44%. This is amongst the best in the industry. INDV outperforms 91.24% of its industry peers.
In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
INDV has a better Gross Margin (83.98%) than 89.18% of its industry peers.
INDV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.44% | ||
| PM (TTM) | N/A | ||
| GM | 83.98% |
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INDV is creating value.
The number of shares outstanding for INDV has been reduced compared to 1 year ago.
The number of shares outstanding for INDV has been reduced compared to 5 years ago.
INDV has a worse debt/assets ratio than last year.
2.2 Solvency
INDV has an Altman-Z score of 2.93. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.93, INDV is in the better half of the industry, outperforming 72.68% of the companies in the same industry.
INDV has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as INDV would need 2.49 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 2.49, INDV belongs to the best of the industry, outperforming 92.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 2.93 |
ROIC/WACC10.83
WACC10.33%
2.3 Liquidity
A Current Ratio of 0.88 indicates that INDV may have some problems paying its short term obligations.
INDV has a Current ratio of 0.88. This is amonst the worse of the industry: INDV underperforms 86.60% of its industry peers.
A Quick Ratio of 0.72 indicates that INDV may have some problems paying its short term obligations.
INDV has a worse Quick ratio (0.72) than 85.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
The earnings per share for INDV have decreased strongly by -1736.71% in the last year.
The earnings per share for INDV have been decreasing by -55.78% on average. This is quite bad
INDV shows a strong growth in Revenue. In the last year, the Revenue has grown by 83.27%.
Measured over the past years, INDV shows a quite strong growth in Revenue. The Revenue has been growing by 8.64% on average per year.
EPS 1Y (TTM)-1736.71%
EPS 3Y-77.57%
EPS 5Y-55.78%
EPS Q2Q%10.81%
Revenue 1Y (TTM)83.27%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%-6.34%
3.2 Future
INDV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.66% yearly.
Based on estimates for the next years, INDV will show a small growth in Revenue. The Revenue will grow by 2.59% on average per year.
EPS Next Y-20.5%
EPS Next 2Y-3.84%
EPS Next 3Y2.76%
EPS Next 5Y5.66%
Revenue Next Year-8.41%
Revenue Next 2Y-2.87%
Revenue Next 3Y-0.2%
Revenue Next 5Y2.59%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
INDV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 10.15 indicates a reasonable valuation of INDV.
83.51% of the companies in the same industry are more expensive than INDV, based on the Price/Forward Earnings ratio.
INDV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.15 |
4.2 Price Multiples
INDV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INDV is cheaper than 98.97% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, INDV is valued cheaply inside the industry as 87.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.62 | ||
| EV/EBITDA | 3.43 |
4.3 Compensation for Growth
INDV has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.84%
EPS Next 3Y2.76%
5. Dividend
5.1 Amount
No dividends for INDV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.47
+0.1 (+0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners86.46%
Inst Owner Change0%
Ins Owners3.78%
Ins Owner ChangeN/A
Market Cap1.93B
Analysts82.5
Price Target15.62 (0.97%)
Short Float %2.61%
Short Ratio2.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.6%
PT rev (3m)3.04%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.15 | ||
| P/S | 0.94 | ||
| P/FCF | 14.62 | ||
| P/OCF | 11.63 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.43 |
EPS(TTM)-0.38
EYN/A
EPS(NY)1.52
Fwd EY9.86%
FCF(TTM)1.06
FCFY6.84%
OCF(TTM)1.33
OCFY8.6%
SpS16.51
BVpS-2.28
TBVpS-2.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4% | ||
| ROE | N/A | ||
| ROCE | 141.62% | ||
| ROIC | 111.88% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 25.44% | ||
| PM (TTM) | N/A | ||
| GM | 83.98% | ||
| FCFM | 6.41% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score5
Asset Turnover1.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.49 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 136% | ||
| Cap/Sales | 1.65% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 30.24% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.93 |
F-Score5
WACC10.33%
ROIC/WACC10.83
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1736.71%
EPS 3Y-77.57%
EPS 5Y-55.78%
EPS Q2Q%10.81%
EPS Next Y-20.5%
EPS Next 2Y-3.84%
EPS Next 3Y2.76%
EPS Next 5Y5.66%
Revenue 1Y (TTM)83.27%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%-6.34%
Revenue Next Year-8.41%
Revenue Next 2Y-2.87%
Revenue Next 3Y-0.2%
Revenue Next 5Y2.59%
EBIT growth 1Y103.89%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year13.79%
EBIT Next 3Y10.08%
EBIT Next 5Y12.03%
FCF growth 1Y473.91%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y374.29%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%